Literature DB >> 6585127

Treatment of malignant brain tumours with ACNU and phenobarbital: continuous infusion of ACNU into internal carotid artery and systemic administration of phenobarbital.

K Yumitori, H Handa, T Teraura, J Yamashita.   

Abstract

Thirteen patients with malignant brain tumours were treated by continuous intra-carotid infusion of ACNU in combination with systemic administration of phenobarbital. This aimed to maintain an ACNU concentration around the tumour cells higher for a relatively longer period and to make an ACNU concentration in the systemic circulation lower. Improvements on clinical states and CT findings were observed in 10 patients. The protective effect of phenobarbital against bone marrow suppression by ACNU was also suggested in this study. No complications were experienced in this treatment. This results strongly suggested that this technique is useful to treat patients with malignant brain tumours.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6585127     DOI: 10.1007/bf01406646

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  7 in total

1.  [Chemotherapy of experimental glioma with nitrosoureas--comparison of water soluble ACNU and lipid soluble me-CCNU (author's transl)].

Authors:  H Hasegawa; T Hayakawa; M Hori; H Nakagawa; H Mogami
Journal:  No To Shinkei       Date:  1977-08

2.  The effect of phenobarbital on the toxicity and tumoricidal activity of CCNU in a murine brain tumor model.

Authors:  P J Muller; C H Tator; M Bloom
Journal:  J Neurosurg       Date:  1980-03       Impact factor: 5.115

3.  Microsomal metabolism of nitrosoureas.

Authors:  D L Hill; M C Kirk; R F Struck
Journal:  Cancer Res       Date:  1975-02       Impact factor: 12.701

4.  The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma pharmacokinetics and biotransformation of BCNU.

Authors:  V A Levin; J Stearns; A Byrd; A Finn; R J Weinkam
Journal:  J Pharmacol Exp Ther       Date:  1979-01       Impact factor: 4.030

5.  Hydroxylation of the carcinostatic 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) by rat liver microsomes.

Authors:  H E May; R Boose; D J Reed
Journal:  Biochem Biophys Res Commun       Date:  1974-03-25       Impact factor: 3.575

6.  Use of enhanced computerized tomography to evaluate osmotic blood-brain barrier disruption.

Authors:  E A Neuwelt; K R Maravilla; E P Frenkel; P Barnett; S Hill; R J Moore
Journal:  Neurosurgery       Date:  1980-01       Impact factor: 4.654

7.  Intra-arterial BCNU chemotherapy for the treatment of malignant gliomas of the central nervous system: a preliminary report.

Authors:  H S Greenberg; W D Ensminger; J F Seeger; G W Kindt; F Chandler; K Doan; S R Dakhil
Journal:  Cancer Treat Rep       Date:  1981 Sep-Oct
  7 in total
  5 in total

1.  Brain necroses after intraarterial chemotherapy and irradiation of malignant gliomas--a complication of both ACNU and BCNU?

Authors:  J C Tonn; K Roosen; W Schachenmayr
Journal:  J Neurooncol       Date:  1991-12       Impact factor: 4.130

2.  Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas. Clinical aspects and critical considerations.

Authors:  L Papavero; F Loew; H Jaksche
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

3.  Treatment of malignant gliomas with surgery, intraarterial chemotherapy with ACNU and radiation therapy.

Authors:  F Vega; L Davila; G Chatellier; J Chiras; F Fauchon; P Cornu; L Capelle; M Poisson; J Y Delattre
Journal:  J Neurooncol       Date:  1992-06       Impact factor: 4.130

4.  Metastatic brain tumour and fibrinopeptides.

Authors:  K Yumitori; H Handa; T Teraura; J Yamashita; K Yamamura
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

5.  Leukoencephalopathy associated with intra-arterial ACNU in patients with gliomas.

Authors:  K Tsuboi; Y Yoshii; A Hyodo; K Takada; T Nose
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.